Dr. Reddy's Laboratories Limited (RDY) Earnings History
Annual and quarterly earnings data from 2001 to 2025
Loading earnings history...
RDY EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
RDY Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 58.5% | 22.1% | 17.4% |
| 2024 | 58.6% | 24.3% | 19.9% |
| 2023 | 56.7% | 23.2% | 18.3% |
| 2022 | 53.1% | 13.7% | 11.0% |
| 2021 | 50.8% | 16.9% | 9.1% |
Download Data
Export RDY earnings history in CSV or JSON format
Free sign-in required to download data
Dr. Reddy's Laboratories Limited (RDY) Earnings Overview
As of May 8, 2026, Dr. Reddy's Laboratories Limited (RDY) reported trailing twelve-month net income of $56.59B, reflecting +1.5% year-over-year growth. The company earned $67.91 per diluted share over the past four quarters, with a net profit margin of 17.4%.
Looking at the long-term picture, RDY's 5-year EPS compound annual growth rate (CAGR) stands at -10.4%, signaling declining earnings. The company achieved its highest annual net income of $56.54B in fiscal 2025, representing a new all-time high.
Dr. Reddy's Laboratories Limited maintains industry-leading profitability with a gross margin of 58.5%, operating margin of 22.1%, and net margin of 17.4%. This margin structure demonstrates strong pricing power and operational efficiency. View revenue history →
Compared to peers including SUN ($835M net income, 2.1% margin), PRGO (-$1.82B net income, -33.5% margin), AMRX ($72M net income, 2.4% margin), RDY has outperformed on profitability metrics. Compare RDY vs SUN →
RDY Earnings vs Peers
Earnings metrics vs comparable public companies
RDY Historical Earnings Data (2001–2025)
25 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $56.54B | +1.5% | $71.84B | $67.77 | 17.4% | 22.1% |
| 2024 | $55.68B | +23.6% | $67.73B | $66.80 | 19.9% | 24.3% |
| 2023 | $45.07B | +91.2% | $57.14B | $54.17 | 18.3% | 23.2% |
| 2022 | $23.57B | +10049.5% | $29.48B | $28.34 | 11.0% | 13.7% |
| 2021 | $232M | -98.8% | $431M | $20.73 | 9.1% | 16.9% |
| 2020 | $19.50B | +3.7% | $15.99B | $117.40 | 11.2% | 9.2% |
| 2019 | $18.80B | +91.7% | $20.89B | $113.09 | 12.2% | 13.6% |
| 2018 | $9.81B | -18.5% | $11.92B | $59.01 | 6.9% | 8.4% |
| 2017 | $12.04B | -39.8% | $13.50B | $72.09 | 8.5% | 9.6% |
| 2016 | $20.01B | -9.8% | $29.62B | $116.98 | 12.9% | 19.1% |
Full RDY Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See RDY's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RDY Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare RDY vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonRDY — Frequently Asked Questions
Quick answers to the most common questions about buying RDY stock.
Is RDY growing earnings?
RDY EPS of $67.91 reflects slowing growth at +1.5%, below the 5-year CAGR of -10.4%. TTM net income is $56.6B. Expansion rate has moderated.
What are RDY's profit margins?
Dr. Reddy's Laboratories Limited net margin is +17.4%, with operating margin at +22.1%. Above-average margins indicate pricing power.
How consistent are RDY's earnings?
RDY earnings data spans 2001-2025. The current earnings trend is +1.5% YoY. Historical data enables comparison across business cycles.